This expands ESTEVE's portfolio of medications for rare and severe diseases with three products to treat Cushing's syndrome and adrenocortical carcinoma; and drives its intern...

The company expects the new facilities to be operational in the last quarter of 2026.

This unit will allow the company's production capacity to increase globally ...

The company advances in its vision to be a leading international specialty pharmaceutical company, growing in Europe and expanding the portfolio

ESTEVE's medicine...